MX2020000625A - Metodos para tratar trastornos microvasculares autoinmunes. - Google Patents

Metodos para tratar trastornos microvasculares autoinmunes.

Info

Publication number
MX2020000625A
MX2020000625A MX2020000625A MX2020000625A MX2020000625A MX 2020000625 A MX2020000625 A MX 2020000625A MX 2020000625 A MX2020000625 A MX 2020000625A MX 2020000625 A MX2020000625 A MX 2020000625A MX 2020000625 A MX2020000625 A MX 2020000625A
Authority
MX
Mexico
Prior art keywords
methods
treating autoimmune
microvascular disorders
autoimmune microvascular
disorders
Prior art date
Application number
MX2020000625A
Other languages
English (en)
Inventor
Robert M Levy
Original Assignee
Primus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primus Pharmaceuticals Inc filed Critical Primus Pharmaceuticals Inc
Publication of MX2020000625A publication Critical patent/MX2020000625A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen métodos para tratar condiciones microvasculares autoinmunes utilizando diosmina o diosmetina, particularmente el tratamiento de úlceras digitales en esclerosis sistémica.
MX2020000625A 2017-07-19 2018-07-18 Metodos para tratar trastornos microvasculares autoinmunes. MX2020000625A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762534237P 2017-07-19 2017-07-19
PCT/US2018/042573 WO2019018455A1 (en) 2017-07-19 2018-07-18 METHODS OF TREATING AUTOIMMUNE MICROVASCULAR DISORDERS

Publications (1)

Publication Number Publication Date
MX2020000625A true MX2020000625A (es) 2020-09-28

Family

ID=65016682

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000625A MX2020000625A (es) 2017-07-19 2018-07-18 Metodos para tratar trastornos microvasculares autoinmunes.

Country Status (12)

Country Link
US (2) US11278517B2 (es)
EP (2) EP3654965B1 (es)
JP (1) JP7237962B2 (es)
KR (1) KR20200051579A (es)
CN (1) CN111065389B (es)
AU (1) AU2018304208B2 (es)
CA (1) CA3069921C (es)
ES (1) ES2957742T3 (es)
HR (1) HRP20231517T1 (es)
MX (1) MX2020000625A (es)
PL (1) PL3654965T3 (es)
WO (1) WO2019018455A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306300A (zh) * 2022-01-04 2022-04-12 上海交通大学医学院附属仁济医院 一种香叶木素的用途及其动物模型的建立方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
WO2004017956A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Dosage forms and related therapies
FR2929276B1 (fr) 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015153648A1 (en) 2014-03-31 2015-10-08 Ingredients By Nature Flavonoid compositions and uses thereof

Also Published As

Publication number Publication date
US20220168267A1 (en) 2022-06-02
EP4269397A3 (en) 2024-01-31
AU2018304208A1 (en) 2020-02-13
US11844777B2 (en) 2023-12-19
EP3654965A1 (en) 2020-05-27
EP3654965B1 (en) 2023-09-06
ES2957742T3 (es) 2024-01-24
CA3069921A1 (en) 2019-01-24
US20200147031A1 (en) 2020-05-14
AU2018304208B2 (en) 2022-03-17
JP7237962B2 (ja) 2023-03-13
KR20200051579A (ko) 2020-05-13
JP2020528454A (ja) 2020-09-24
EP3654965A4 (en) 2021-03-10
US11278517B2 (en) 2022-03-22
PL3654965T3 (pl) 2024-02-26
CN111065389A (zh) 2020-04-24
HRP20231517T1 (hr) 2024-03-01
CN111065389B (zh) 2023-11-21
CA3069921C (en) 2022-01-18
EP4269397A2 (en) 2023-11-01
WO2019018455A1 (en) 2019-01-24
EP3654965C0 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2021000077A (es) Composiciones que comprenden cepas bacterianas.
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
MX2018006239A (es) Composiciones que comprenden cepas bacterianas.
MX2018006398A (es) Composiciones que comprenden cepas bacterianas.
MX2018006399A (es) Composiciones que comprenden cepas bacterianas.
MX2017016529A (es) Composiciones que comprenden cepas bacterianas.
MX2017016564A (es) Composiciones que comprenden cepas bacterianas.
MX2017016560A (es) Composiciones que comprenden cepas bacterianas.
MX2017016525A (es) Composiciones que comprenden cepas bacterianas.
MX2020001406A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
ZA201800056B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
GB2541571A (en) Pharmaceutical compositions
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
WO2016077639A3 (en) Nanovesicular therapies
SA518391831B1 (ar) تركيبات وطرق لخفض تعبير البروتين تاو
PH12017501028A1 (en) Treatment of retinal degeneration using progenitor cells
PH12017501980A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
AU2017277478A1 (en) Pharmaceutical combinations for treating cancer
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
MX2016016793A (es) Discos de aireacion y metodos para usar los mismos.
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.